CSE: TRUE OTC: TREIF 939: FRA

Treatment.com AI Announces Non-Brokered Private Placement of up to $1,750,000 of Special Warrants

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States. Vancouver, British Columbia, October 4, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that it is undertaking a non-brokered private placement of up to 2,333,333 special warrants of the Company (each, a “Special Warrant”) at a price of $0.75 per Special Warrant, for aggregate gross proceeds of up to $1,750,000 the (“Offering”). Each Special Warrant will automatically convert into one unit of the Company (each a “Unit”). Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $1.00 per Share for a period of 24 months following the date of issuance of the Warrants. Each Special Warrant will automatically convert, for no additional consideration, into Units on the date (the “Conversion Date”) that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the “Prospectus Supplement”) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date. The Company will use its commercially reasonable efforts to file the Prospectus Supplement to qualify the distribution of the Shares and Warrants issuable upon conversion of the Special Warrants within 60 days of the closing of the Offering (not including the date of closing). The Company may pay a finder’s fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants (the “Broker Warrants”) equal up to 8% of the number of Special Warrants sold under the Offering. Each Broker Warrant will entitle the holder to purchase one Share (a “Broker Share”) at an exercise price of $1.00 per Broker Share for a period of 24 months from the date of issuance of the Broker Warrants. The Company intends to use the proceeds raised from the Offering for working capital purposes. The Offering is expected to close on or before October 11, 2024. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Prior to the filing of the Prospectus Supplement and the automatic conversion of the Special Warrants, all securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. The securities being referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@www.treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@www.treatment.com For media inquiries, contact: media@www.treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking

Treatment.com AI to Present at the 2024 Cantech Letter Conference in Toronto,ON

Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024. VANCOUVER, British Columbia (Newsfile Corp. – October 1, 2024) – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”), a healthcare tech company focused on  transforming patient care with AI-driven Clinical insights, is pleased to announce its participation at the upcoming Cantech Letter Investment Conference on Wednesday, October 9, 2024 in Toronto Ontario. Dr. Essam Hamza, CEO of Treatment.com AI , will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors at the conference. 2024 Cantech Letter Conference Date: Wednesday, October 9, 2024 Time: 11:00 AM Eastern Time in Track 1 Location: Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON Contact: tara@cantechletter.com to register More info: https://www.cantechletter.com/conference/ Dr. Essam Hamza, CEO of Treatment.com AI, commented, “We are looking forward to presenting at Cantech, a great conference providing a timely opportunity to talk to investors, analysts and the investment community. The healthcare system is at the precipice of substantial modernization and we believe that our proprietary platform can help with reducing its inefficiencies, reducing administration headaches, and ultimately improving patient access and care.” Dr. Essam Hamza will also be conducting in-person 1×1 meetings at the conference venue on Wednesday, October 9, 2024. To schedule 1-on-1 investor meetings with Treatment and attend the 2024 Cantech Letter Conference, please contact Tara Whittet at tara@cantechletter.com. 1×1 meetings will be conducted in person at the conference venue: Arcadian Loft, Toronto. About Cantech Letter Conference The Cantech Letter Conference, recognized as Canada’s foremost technology investment event, provides up and coming technology companies with the unique opportunity to showcase their innovations and growth strategies, and participate in individual 1-on-1 meetings with potential investors and capital markets professionals. The conference serves as a hub for networking, knowledge exchange, and investment opportunities, while also featuring panel discussions with industry experts to offer insights into current trends, challenges, and opportunities within the technology sector. About Treatment.com AI Inc. Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@www.treatment.com FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@www.treatment.com For media inquiries, contact: media@www.treatment.com Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates.  Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Treatment.com AI Medical Education Corporate Update and Updates on Additional Marketing Engagements

OSCE (Objective Structured Clinical Examination) now adopted in over 80 countries and with upwards of 200k students annually Lead commercial participant at Global/North American Symposium on AI Assessment in Medical Education AI Assessment in Medical Education Symposium New solutions on track for H2 2024 (AI Patient/Doctor in Pocket) VANCOUVER, British Columbia, September 26th, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the medical education sector. Marketing Updates The Company announces that further to its news releases of July 2nd, September 5th, and 17th, 2024, the Company provides the following additional information required by Canadian Securities Exchange Policy 7 regarding its marketing engagements of Leit Media Ltd. (“Leit”) and Interactive Media Group. (“IMG”). Leit: On July 2, 2024, the Company announced that it had engaged Leit, to provide, news release translation, investor relations and email marketing services with a focus on the German stock market and the German-speaking investor community for an initial period of six months commencing July 1, 2024 and ending on January 1, 2025, in consideration of EUR 250,000, and pursuant to an agreement dated July 1, 2024. Leit does not currently own any interest, directly or indirectly, in the Company or its securities. Leit’s address is Flat 285, 61 Praed St., London, W2 1NS, United Kingdom (phone: 44-20-3883-9398, email: office@leit.media). Consideration offered to Leit does not include any securities of the Company, including options. Leit and its directors and officers are arm’s length from the Company. On September 5, 2024, the Company announced that it has amended the marketing/investor relations agreement with Leit, as previously announced by the Company on July 2, 2024. Pursuant to the amended agreement, the Company will provide an additional amount of EUR 250,000 to Leit for the digital marketing campaign and the campaign will continue to focus on the German speaking investor community. The campaign shall still run from July 1, 2024 to Januarty 1, 2025. Leit will also translate the Company’s news releases into German. IMG: On September 17, 2024, the Company announced that it has engaged IMG to conduct a marketing awareness program for the Company for a period of one (1) month commencing on September 24, 2024 and ending on October 24, 2024, in consideration of a payment of US$23,000. IMG does not currently own any interest, directly or indirectly, in the Company or its securities. IMG’s address is 9330 LBJ Freeway, Dallas, Texas, USA (phone: (214)253-8522, email: support@imginc.org). Consideration offered to IMG does not include any securities of the Company, including options. IMG and its directors and officers are arm’s length from the Company. IMG’s marketing awareness services shall consist of creating email marketing campaigns and brand marketing services. Market Background – Medical Education It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. These include the United States; United Kingdom; Canada; Australia and New Zealand; Europe (e.g., Ireland, Germany, Netherlands); Middle East (e.g. Saudi Arabia and the UAE) and Asia (e.g. India, China, Japan, and Malaysia). It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including:  https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/;  Education – GMC (gmc-uk.org) For the past 3 years, Treatment has provided OSCE services to Medical Schools, including the University of Minnesota. The service comprises of using our Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for the actors playing the role of patients (iii) scoring the exams with our proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. Upcoming Symposium on AI Assessment in Medical Education To further underscore its commitment to supporting the next generation of healthcare professionals, Treatment will be a lead participant in an upcoming Symposium on AI Assessment in Medical Education AI Assessment in Medical Education Symposium. The University of Minnesota has confirmed the event will be invitation only, with no media attending. One of the key proponents for advancements in medical education and orchestrators of the Symposium, Dr Claudio Violato comments: “AI is revolutionizing assessment in medical education by automating grading processes and formative feedback, assessing clinical skills, and diagnosing deficits in learner performance. AI-powered virtual patients offer realistic scenarios for practice, enhancing clinical decision-making skills without risking patient safety. This landmark symposium will bring experts to the University of Minnesota Medical School on November 1 with a focus on the use of generative AI to produce test questions and clinical assessments; machine scoring and analysis of learner responses to audio-video capture of clinical performance in the workplace (e.g., wards, clinics, etc.); and clinical notes. The symposium will take the next step in the evolution of AI applications to medical education to produce physicians of the highest caliber”. Events | Medical Education Office of Assessment & Evaluation (umn.edu) Claudio Violato, PhD, Professor and Assistant Dean for Assessment and Evaluation, University of Minnesota Medical Education Office of Assessment and Evaluation Medical Education Suite (MES) Update Treatment has worked diligently over the past two quarters to ensure continued evolution of its Medical Education Suite (MES), powered by its Global Library of Medicine (GLM). The company remains on track for release of its previously announced two new monthly subscription-based SaaS solutions for students, residents and all healthcare professionals in the second half of 2024: AI Patient – utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We look